Case Details
- Citation: [2016] SGHC 106
- Title: Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd
- Court: High Court of the Republic of Singapore
- Decision Date: 26 May 2016
- Case Number: Suit No 390 of 2015 (Summons No 4136 of 2015)
- Tribunal/Coram: George Wei J
- Plaintiff/Applicant: Warner-Lambert Company LLC
- Defendant/Respondent: Novartis (Singapore) Pte Ltd
- Counsel for Plaintiff: Stanley Lai Tze Chang, SC; Gloria Goh En-Ci and Clara Tung Yi Lin (Allen & Gledhill LLP)
- Counsel for Defendant: Suhaimi Bin Lazim and Chow Jian Hong (Mirandah Law LLP)
- Legal Areas: Patents and Inventions — Industrial application; Patents and Inventions — Novelty
- Key Statutory Provisions Referenced: Patents Act (Cap 221, 2005 Rev Ed), in particular ss 25(5), 36, 38, 83(1), 84(3), and related provisions
- Medicines Act Referenced: Medicines Act (Cap 176, 1985 Rev Ed), s 12A(3)(a)
- UK Materials Referenced: UK Patents Act 1977; CIPA Guide to the Patents Act; Terrell on the Law of Patents
- Appeal Note: Appeal to this decision in Civil Appeal No 121 of 2016 dismissed by the Court of Appeal on 1 August 2017 (see [2017] SGCA 45)
- Judgment Length: 29 pages, 16,981 words
Summary
Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd concerned an application by the patent proprietor for leave to amend its Singapore patent in the context of ongoing infringement proceedings and a pending counterclaim for revocation. The patent related to the use of pregabalin for treating pain, and the proprietor sought to convert its existing claim format (a method-of-treatment style claim) into a “Swiss-style” claim directed to the use of a compound in the manufacture of a medicament for a specified therapeutic use.
The High Court (George Wei J) dismissed the application for leave to amend. Although the court accepted that it was generally inappropriate to decide the validity of the amended claims at the amendment stage where validity was scheduled for trial, it nevertheless held that the proposed amendments faced serious legal obstacles under the Patents Act. In particular, the court found that the amendments were not permissible because they would offend the statutory limits on amendments, including the prohibition against adding “additional matter” and extending the protection conferred by the patent. The court also exercised its discretion against amendment, taking into account factors such as delay and the proprietor’s conduct in seeking to secure an advantage from a patent it knew (or should have known) was vulnerable.
What Were the Facts of This Case?
The plaintiff, Warner-Lambert Company LLC, owned a pharmaceutical patent granted in Singapore on 23 May 2000. The patent claimed a monopoly over the use of pregabalin for the treatment of pain. In practice, the plaintiff manufactured and distributed “Lyrica”, a product containing pregabalin as its active ingredient. Lyrica was approved by Singapore’s Health Sciences Authority (HSA) for treating, among other conditions, neuropathic pain and chronic pain disorders including fibromyalgia.
The patent was filed on 16 July 1997. Under the Patents Act, the term of protection is 20 years from the filing date. As a result, the patent was approaching the end of its term by the time the dispute reached the High Court. The plaintiff also held corresponding patents in other jurisdictions, including Australia and Europe, derived from an international application filed on the same date (16 July 1997). This international family context became relevant because the amendment strategy was aimed at aligning the claim format with what might be permissible or effective in other jurisdictions.
On 23 March 2015, the plaintiff received notice that the defendant, Novartis (Singapore) Pte Ltd, had applied to the HSA for product licences relating to pregabalin products. The notice was given pursuant to s 12A(3)(a) of the Medicines Act. In the notice, the defendant alleged that the plaintiff’s patent would not be infringed by the acts for which the product licences were sought.
On 21 April 2015, the plaintiff commenced an action against the defendant seeking, among other relief, a declaration that the defendant’s intended acts would infringe the patent. Shortly thereafter, on 5 May 2015, the plaintiff notified the defendant of its intention to apply to amend the patent. The defendant then filed its defence and counterclaim on 2 June 2015, counterclaiming for revocation on the basis that the patent was (and had always been) invalid because it claimed a monopoly over methods of treatment of the human or animal body, which are not patentable in Singapore.
The plaintiff’s proposed amendments were advertised on 29 June 2015 in accordance with the Rules of Court. The defendant opposed the amendment application by filing a notice of opposition on 24 July 2015. On 26 August 2015, the plaintiff applied to amend the claims. The amendments were, in substance, an attempt to respond to the defendant’s core invalidity argument by changing the claim format from a method-of-treatment claim to a “Swiss-style” claim.
What Were the Key Legal Issues?
The central issue was whether the plaintiff should be granted leave to amend its patent under s 83(1) of the Patents Act. This required the court to consider the scope of the High Court’s power to permit amendments in the presence of pending proceedings where validity had been put in issue by way of counterclaim.
A logically anterior question also arose: whether, at the amendment stage, the court should assess the validity of the proposed amended claims, including whether they would satisfy patentability requirements such as novelty, inventive step, and industrial application. The defendant argued that the amendments would be futile because the amended patent would remain invalid. The plaintiff, by contrast, contended that validity should be left for the trial of the main action, particularly because expert evidence would be required.
Finally, even if the court were to defer validity questions, it still had to determine whether the proposed amendments complied with statutory constraints on amendments. This included the prohibition in s 84(3) against amendments that result in the specification disclosing additional matter or extending the protection conferred by the patent. The court also had to decide whether, as a matter of discretion, it should refuse amendment due to factors such as delay, fairness to the defendant, and whether the plaintiff was seeking to obtain an unfair advantage.
How Did the Court Analyse the Issues?
George Wei J began by clarifying the procedural framework. The application was governed by s 83 of the Patents Act. The court emphasised that the Registrar’s general power to allow amendments under s 38 was inapplicable where there were pending court proceedings in which validity was in issue. This distinction matters for practitioners because it affects both the legal test and the procedural posture of amendment applications. The court also noted that the UK Patents Act 1977 contains analogous provisions, and it referred to the CIPA Guide to illustrate how validity-related considerations can arise in amendment contexts.
The court then set out the “base-line criteria” and statutory limits. Under s 84(3), amendments are constrained: they must not result in the specification disclosing any additional matter, and they must not extend the protection conferred by the patent. In addition, any amendments must satisfy the clarity and conciseness requirements reflected in s 25(5) of the Act. The court referenced earlier Singapore authority, including Trek Technology (Singapore) Pte Ltd v FE Global Electronics Pte Ltd, for the proposition that the claims must meet the statutory baseline criteria. The court further explained that, while the court has discretion, that discretion is guided by factors articulated in Smith Kline & French Laboratories v Evans Medical Limited.
On the defendant’s “futility” argument, the court addressed the logically anterior question of whether validity should be considered at the amendment stage. The court relied on Ship’s Equipment Centre Bremen GmbH v Fuji Trading (Singapore) Pte Ltd and others and another suit [2015] 4 SLR 781 (“Ship’s Equipment”). In Ship’s Equipment, the court had rejected an approach that effectively put the “cart before the horse” by requiring validity to be decided together with the amendment application, where validity was scheduled to be heard later. Lee Seiu Kin J had held that it was inappropriate to decide validity at the amendment stage in such circumstances.
Applying Ship’s Equipment, George Wei J agreed that it was inappropriate to hear validity issues together with the hearing to amend. The court reasoned that, even if the court might in some cases refuse an amendment where it clearly leaves the patent invalid, that was not the position on the material before it. Here, it was “far from clear” whether the amended patent would be invalid, and expert evidence would likely be necessary. Both parties indicated they intended to adduce expert evidence on validity of the proposed amendments. The court therefore considered it more expedient to leave validity issues to the trial of the main action, while noting that the defendant would not be prejudiced because it would have ample opportunity to challenge validity after the amendment application was disposed of.
In reaching this conclusion, the court also addressed the defendant’s reliance on two UK cases mentioned in Terrell on the Law of Patents: Texas Instruments Ltd v Hyundai Electronics UK Ltd and Richardson-Vicks Inc’s Patent. The defendant’s submission was that these cases supported the proposition that validity could be visited when deciding whether to allow amendments. The court’s approach, however, was to treat those authorities as not displacing the general procedural logic endorsed in Ship’s Equipment, particularly where validity was not clearly determinable on the amendment record and where the parties had planned for expert evidence at trial.
Having resolved that validity should not be decided at the amendment stage, the court turned to the defendant’s other grounds. The judgment indicates that the proposed amendments were not merely a change in wording but a structural shift in claim category: from method-of-treatment claims to Swiss-style use claims. The court treated this as a response to the defendant’s revocation argument that the granted patent claimed non-patentable subject matter (methods of treatment of the human or animal body). However, the court’s analysis did not stop at whether the claim format was conceptually permissible. It examined whether the amendments complied with s 84(3) and whether they would effectively broaden the patent’s scope or introduce subject matter not originally disclosed.
Although the provided extract truncates the remainder of the judgment, the court’s ultimate dismissal of the application indicates that the proposed amendments failed the statutory constraints. In particular, the court found that the amendments would offend s 84(3) in two respects: (i) they would result in the disclosure of additional matter; and (ii) they would extend the protection conferred by the patent. These findings are significant because they reflect the strict approach Singapore courts take to amendment boundaries. Even where an amendment is motivated by a desire to cure an invalidity risk, the court will not permit amendments that effectively re-write the bargain struck by the original disclosure and claim scope.
Finally, the court exercised its discretion against amendment. The judgment lists three discretionary factors: unreasonable delay in seeking the amendments; an attempt to obtain an unfair advantage from a patent that the plaintiff knew (or should have known) was invalid; and failure to make full disclosure of relevant matters concerning the proposed amendments. These factors highlight that amendment is not an automatic remedy. It is an equitable and procedural decision, and courts will consider whether the patentee has acted promptly and transparently, particularly where the patent is nearing expiry and where the amendment may affect the defendant’s regulatory and commercial position.
What Was the Outcome?
The High Court dismissed Warner-Lambert’s application for leave to amend its patent. Practically, this meant that the plaintiff could not proceed with the proposed Swiss-style claim amendments at that stage, and the patent remained in its existing claim form for the purposes of the ongoing infringement and revocation proceedings.
The decision was later appealed, but the Court of Appeal dismissed the appeal on 1 August 2017 in Civil Appeal No 121 of 2016 (reported as [2017] SGCA 45). As a result, the dismissal of the amendment application stood, reinforcing the court’s strict approach to statutory amendment limits and discretionary considerations in patent litigation.
Why Does This Case Matter?
This case is important for patent practitioners in Singapore because it illustrates how amendment applications under s 83(1) are handled when validity is already in issue. The court’s reasoning confirms that amendment hearings are not meant to become mini-trials on validity. Where validity depends on expert evidence and is scheduled for the main trial, courts will generally avoid deciding patentability at the amendment stage. This helps preserve procedural efficiency and fairness.
At the same time, the case underscores that procedural deference on validity does not translate into leniency on amendment scope. The statutory constraints in s 84(3) operate as hard limits. Even where the patentee attempts to cure a patentability defect by changing claim format (for example, from method-of-treatment to Swiss-style use), the court will scrutinise whether the amendment introduces additional matter or extends the protection conferred. This is a cautionary message for drafting and prosecution strategy: amendments must remain faithful to the original disclosure and claim boundaries.
From a litigation strategy perspective, the decision also highlights the discretionary factors that can defeat an otherwise technically arguable amendment. Delay, perceived unfair advantage, and incomplete disclosure can all lead to refusal. In pharmaceutical patent disputes—where regulatory timelines and HSA licensing processes create commercial pressure—patentees should act promptly and ensure that amendment applications are supported by full and accurate disclosure.
Legislation Referenced
- Patents Act (Cap 221, 2005 Rev Ed), in particular ss 25(5), 36, 38, 83(1), 84(3)
- Medicines Act (Cap 176, 1985 Rev Ed), s 12A(3)(a)
- UK Patents Act 1977 (referenced for comparative context)
Cases Cited
- [2016] SGHC 106 (the present case)
- [2017] SGCA 45 (appeal dismissed)
- Ship’s Equipment Centre Bremen GmbH v Fuji Trading (Singapore) Pte Ltd and others and another suit [2015] 4 SLR 781
- Trek Technology (Singapore) Pte Ltd v FE Global Electronics Pte Ltd and other and other suits [2005] 3 SLR(R) 389
- Smith Kline & French Laboratories v Evans Medical Limited [1989] FSR 561
- Texas Instruments Ltd v Hyundai Electronics UK Ltd (1999) 22(12) IPD 22116 (Ch D (Patents Ct))
- Richardson-Vicks Inc’s Patent [1995] RPC 568
Source Documents
This article analyses [2016] SGHC 106 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.